OLMA Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About OLMA Interactive Breakdown Better Bets vs. OLMA Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Olema Pharmaceuticals (OLMA)

    Market Price (7/22/2026): $11.58 | Market Cap: $1.2 BilSector: Health Care | Industry: Biotechnology

    Olema Pharmaceuticals (OLMA)

    Market Price (7/22/2026): $11.58
    Market Cap: $1.2 Bil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -42%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -54%, 3Y Excs Rtn is -25%

    Meaningful short interest
    Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -202 Mil

    Stock price has recently run up significantly
    12M Rtn12 month market price return is 153%

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20%

    High stock price volatility
    Vol 12M is 160%

    Key risks
    OLMA key risks include [1] binary Phase 3 results for its lead drug palazestrant, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -42%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -54%, 3Y Excs Rtn is -25%
    3 Meaningful short interest
    Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14%
    4 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    5 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -202 Mil
    6 Stock price has recently run up significantly
    12M Rtn12 month market price return is 153%
    7 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -20%
    8 High stock price volatility
    Vol 12M is 160%
    9 Key risks
    OLMA key risks include [1] binary Phase 3 results for its lead drug palazestrant, Show more.

    OLMA in ETFs

    Weight = OLMA's share of each fund

    VTI0.00%
    ITOT0.00%
    IWM0.03%
    XBI0.30%
    IBB0.06%
    IWN0.05%
    VTWO0.03%
    DFAS0.02%
    +7 more covered ETFs

    Valuation & Metrics

    FYE: 12/31OLMA [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$2.2 Mil—
    FY 2027 Sales$23.1 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth927.7%8.2%
    EARNINGS
    LTM Net Income (GAAP) [3]$-185.2 Mil—
    FY 2026 Net Income (Non-GAAP)$-193.6 Mil—
    FY 2027 Net Income (Non-GAAP)$-216.9 Mil—
    FY 2027 Net Income Growth—16.4%
    FY 2026 EPS (Non-GAAP)$-2.21—
    FY 2027 EPS (Non-GAAP)$-2.40—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S529.13.2
    FY 2027 P/S51.5—
    FY 2026 P/E—19.6
    FY 2027 P/E——

    [1] OLMA forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 7/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Patients Enrolled in Phase 1b/2 Trial of palazestrant with ribociclib727082025Link
    Number of Phase 3 Clinical Trials for palazestrant (OP-1250)211032025Link
    Number of Phase 1 Clinical Studies for OP-3136111032025Link
    Employee Count9611072025Link

    Price Chart

    null
    Upcoming
    8/10/2026Earnings ReleaseRev: -
    EPS: -

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 7/16/2026

    Olema Pharmaceuticals (OLMA) stock has lost about 20% since 3/31/2026 because of the following key factors:

    1. Accelerated Operating Losses Driven by Increased R&D Expenses.

    Olema Pharmaceuticals, a clinical-stage company with no product sales, reported a widening net loss in fiscal Q1 2026, reaching $(53.1) million. This represented a deterioration from a net loss of $(30.4) million in fiscal Q1 2025, with the diluted loss per share increasing by 44.4% year-over-year from $(0.36) to $(0.52). The increased loss was primarily due to higher research and development (R&D) spending and headcount to support late-stage clinical trials for palazestrant (OPERA-01 and OPERA-02) and early-stage studies for OP-3136, indicating significant cash burn as the company advances its pipeline.

    2. Anticipation of Key Clinical Trial Data Further in Fiscal 2026.

    A significant near-term catalyst, the top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant (OP-1250) as a monotherapy, is not expected until "fall 2026." The period since March 31, 2026 (covering fiscal Q2 2026), did not include this high-impact data readout. While initial clinical results from the Phase 1 study of OP-3136 were presented in May 2026 at ASCO, showing encouraging tolerability and anti-tumor activity across multiple solid tumor types, this early-stage data may not have been sufficient to significantly bolster investor confidence against the backdrop of increased operating losses and the waiting period for the more advanced palazestrant data.

    Show more
    Updated on 7/16/2026

    Olema Pharmaceuticals (OLMA) stock has lost about 20% since 3/31/2026 because of the following key factors:

    1. Accelerated Operating Losses Driven by Increased R&D Expenses.

    Olema Pharmaceuticals, a clinical-stage company with no product sales, reported a widening net loss in fiscal Q1 2026, reaching $(53.1) million. This represented a deterioration from a net loss of $(30.4) million in fiscal Q1 2025, with the diluted loss per share increasing by 44.4% year-over-year from $(0.36) to $(0.52). The increased loss was primarily due to higher research and development (R&D) spending and headcount to support late-stage clinical trials for palazestrant (OPERA-01 and OPERA-02) and early-stage studies for OP-3136, indicating significant cash burn as the company advances its pipeline.

    2. Anticipation of Key Clinical Trial Data Further in Fiscal 2026.

    A significant near-term catalyst, the top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant (OP-1250) as a monotherapy, is not expected until "fall 2026." The period since March 31, 2026 (covering fiscal Q2 2026), did not include this high-impact data readout. While initial clinical results from the Phase 1 study of OP-3136 were presented in May 2026 at ASCO, showing encouraging tolerability and anti-tumor activity across multiple solid tumor types, this early-stage data may not have been sufficient to significantly bolster investor confidence against the backdrop of increased operating losses and the waiting period for the more advanced palazestrant data.

    3. Analyst Price Target Adjustments.

    Despite a general "Strong Buy" or "Moderate Buy" consensus rating from analysts, some firms adjusted their price targets downwards during or immediately prior to the specified period. For example, Guggenheim lowered its price target from $38 to $35 on May 13, 2026, and Goldman Sachs reduced its target from $38 to $27 on March 18, 2026. These downward revisions in price targets, even while maintaining positive ratings, likely contributed to a re-evaluation of the stock's near-term valuation by investors, putting downward pressure on the share price.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -22.3% change in OLMA stock from 3/31/2026 to 7/21/2026 was primarily driven by a -11.1% change in the company's Shares Outstanding (Mil).
    (LTM values as of)33120267212026Change
    Stock Price ($)14.9111.59-22.3%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)91103-11.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    3/31/2026 to 7/21/2026
    ReturnCorrelation
    OLMA-22.3% 
    Market (SPY)15.1%26.5%
    Sector (XLV)9.3%15.3%

    Fundamental Drivers

    The -53.6% change in OLMA stock from 12/31/2025 to 7/21/2026 was primarily driven by a -16.6% change in the company's Shares Outstanding (Mil).
    (LTM values as of)123120257212026Change
    Stock Price ($)25.0011.59-53.6%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)86103-16.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    12/31/2025 to 7/21/2026
    ReturnCorrelation
    OLMA-53.6% 
    Market (SPY)10.0%24.9%
    Sector (XLV)3.9%19.2%

    Fundamental Drivers

    The 172.1% change in OLMA stock from 6/30/2025 to 7/21/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)63020257212026Change
    Stock Price ($)4.2611.59172.1%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)85103-16.9%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    6/30/2025 to 7/21/2026
    ReturnCorrelation
    OLMA172.1% 
    Market (SPY)22.1%1.8%
    Sector (XLV)20.4%13.7%

    Fundamental Drivers

    The 28.3% change in OLMA stock from 6/30/2023 to 7/21/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)63020237212026Change
    Stock Price ($)9.0311.5928.3%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)40103-60.7%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    6/30/2023 to 7/21/2026
    ReturnCorrelation
    OLMA28.3% 
    Market (SPY)74.8%11.0%
    Sector (XLV)26.4%17.8%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    OLMA Return-81%-74%473%-58%329%-55%-76%
    Peers Return-8%-31%-24%-16%-9%-1%-63%
    S&P 500 Return27%-19%24%23%16%9%98%

    Monthly Win Rates [3]
    OLMA Win Rate25%33%75%25%58%14% 
    Peers Win Rate42%48%42%48%50%51% 
    S&P 500 Win Rate75%42%67%75%67%43% 

    Max Drawdowns [4]
    OLMA Max Drawdown-84%-78%-35%-66%-54%-69% 
    Peers Max Drawdown-59%-69%-66%-58%-69%-37% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: ARVN, VERU, ZYME, KPTI, CLDX.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 7/21/2026 (YTD)

    How Low Can It Go

    EventOLMAS&P 500
    2025 US Tariff Shock
      % Loss-40.7%-18.8%
      % Gain to Breakeven68.6%23.1%
      Time to Breakeven22 days79 days
    2023 SVB Regional Banking Crisis
      % Loss-32.8%-6.7%
      % Gain to Breakeven48.8%7.1%
      Time to Breakeven23 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-78.4%-24.5%
      % Gain to Breakeven362.3%32.4%
      Time to Breakeven413 days427 days

    Compare to ARVN, VERU, ZYME, KPTI, CLDX

    In The Past

    Olema Pharmaceuticals's stock fell -40.7% during the 2025 US Tariff Shock. Such a loss loss requires a 68.6% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventOLMAS&P 500
    2025 US Tariff Shock
      % Loss-40.7%-18.8%
      % Gain to Breakeven68.6%23.1%
      Time to Breakeven22 days79 days
    2023 SVB Regional Banking Crisis
      % Loss-32.8%-6.7%
      % Gain to Breakeven48.8%7.1%
      Time to Breakeven23 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-78.4%-24.5%
      % Gain to Breakeven362.3%32.4%
      Time to Breakeven413 days427 days

    Compare to ARVN, VERU, ZYME, KPTI, CLDX

    In The Past

    Olema Pharmaceuticals's stock fell -40.7% during the 2025 US Tariff Shock. Such a loss loss requires a 68.6% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Olema Pharmaceuticals (OLMA)

    Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for women's cancers. As a company in the clinical development phase, its core business revolves around advancing potential drug candidates through rigorous research and clinical trials with the goal of bringing new treatments to patients.

    The company's primary product candidate is OP-1250, an investigational drug designed to act as an estrogen receptor (ER) antagonist and a selective ER degrader. OP-1250 is currently in Phase 1/2 clinical trials, evaluating its potential as a treatment for recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

    Olema Pharmaceuticals serves the pharmaceutical and healthcare market, specifically targeting the oncology sector with a focus on women's cancers. Its eventual customers, upon successful development and regulatory approval, would be medical professionals, such as oncologists and other healthcare providers, who treat patients with advanced ER-positive breast cancer.

    AI Analysis | Feedback

    Here are 1-2 brief analogies for Olema Pharmaceuticals:

    • An early-stage Seagen for women's cancer treatments.

    • A developing Incyte specializing in women's cancer drugs.

    AI Analysis | Feedback

    • OP-1250: A lead drug candidate in Phase 1/2 clinical trials, developed as an estrogen receptor antagonist and selective ER degrader for the treatment of certain types of breast cancer.

    AI Analysis | Feedback

    Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company. As described, its lead product candidate, OP-1250, is currently in Phase 1/2 clinical trials. This means the company is primarily engaged in the discovery and development of therapies and has not yet commercialized any products.

    Therefore, Olema Pharmaceuticals does not currently have major customers that purchase its products or services. Its activities are focused on research and development to bring its drug candidates through clinical trials and regulatory approval.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Sean Bohen, M.D., Ph.D. President and Chief Executive Officer and Interim Principal Financial Officer
    Dr. Bohen was appointed President and Chief Executive Officer of Olema Pharmaceuticals in September 2020 and led the company's IPO in November 2020. A medical oncologist and biochemist by training, he previously served as Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca for approximately five years and led early development at Genentech for about 13 years.

    Shane Kovacs Former Chief Operating and Financial Officer
    Mr. Kovacs departed Olema Pharmaceuticals as Chief Operating and Financial Officer on January 30, 2026, to pursue new opportunities, but will continue in a consulting role with the company through August 1, 2026. He joined Olema in 2020 and contributed to guiding the company's lead product candidate, palazestrant, through late-stage clinical development, building the finance team, and establishing a strong capital position.

    David Myles, Ph.D. Chief Discovery and Non-Clinical Development Officer

    Naseem Zojwalla, M.D. Chief Medical Officer

    Shawnte Mitchell, J.D. Chief Legal Officer and Corporate Secretary

    AI Analysis | Feedback

    The key risks to Olema Pharmaceuticals (OLMA) are primarily associated with the inherent uncertainties of clinical-stage biopharmaceutical development, particularly concerning its lead product candidate, palazestrant (OP-1250).

    1. Clinical Trial Failure and Regulatory Approval Risk

    Olema Pharmaceuticals is a clinical-stage company with no products currently approved for commercial sale, making its value heavily dependent on the successful progression and eventual regulatory approval of its lead drug candidate, palazestrant. The company's future is significantly tied to the outcomes of its clinical trials, including the pivotal Phase 3 OPERA-01 study. A recent example highlighting this risk was the substantial decline in OLMA's stock (falling by -25.75% to -41%) following the disappointing results of a competitor's (Roche's giredestrant) similar drug in a late-stage Phase 3 clinical trial. This event raised concerns among investors about the entire class of selective estrogen receptor degraders (SERDs) that Olema is developing, even though palazestrant is a distinct molecule. Any setbacks in these trials, such as lack of efficacy, safety concerns, or failure to meet primary endpoints, could severely impact the company's prospects and stock price.

    2. Competition

    Olema operates in a competitive landscape, contending with other developers of oral SERDs and established endocrine therapies for breast cancer. The market share for palazestrant, if approved, will depend on its performance in pivotal trials, subsequent regulatory approvals, and its pricing compared to existing standards of care. The failure of a competitor's drug, as seen with Roche's giredestrant, underscores the intense competition and the potential for negative sentiment to impact the entire drug class, regardless of direct product differences. Olema must differentiate palazestrant in terms of efficacy and safety to succeed against both current treatments and other emerging therapies.

    3. Capital Needs and Operating Losses

    As a clinical-stage biopharmaceutical company without approved products or product revenue, Olema Pharmaceuticals consistently incurs significant net losses and requires substantial additional capital to fund its operations and ongoing research and development programs. Analysts anticipate widening losses as the company advances its lead drug candidate through late-stage trials. The intensive cash burn associated with drug development means that the company may need to secure additional financing, potentially through selling new shares, which could dilute the value for existing stockholders. Failure to raise necessary capital on favorable terms could force Olema to delay or discontinue critical development programs, directly impacting its future growth and valuation.

    AI Analysis | Feedback

    Major pharmaceutical companies are developing advanced oral selective estrogen receptor degrader (SERD) therapies for ER-positive, HER2-negative breast cancer that are significantly further along in clinical development than Olema's lead candidate, OP-1250. For instance, oral SERDs such as Arvinas/Pfizer's vepdegestrant, Eli Lilly's imoventant, and Roche's giredestrant are currently in Phase 3 clinical trials, while OP-1250 is in Phase 1/2. Should these competitors successfully complete their pivotal trials and gain regulatory approval, they could establish a dominant market position for oral SERDs, potentially limiting the future market opportunity and commercial viability for OP-1250.

    AI Analysis | Feedback

    Olema Pharmaceuticals (NASDAQ: OLMA) is developing OP-1250 (palazestrant), an estrogen receptor (ER) antagonist and selective ER degrader for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The addressable market for ER-positive, HER2-negative breast cancer is significant. In the United States, the total market size for ER+/HER2- breast cancer was estimated at USD 6,759 million in 2022 and is projected to grow through 2036. Globally, the HER2-negative breast cancer market was valued at approximately US$14.4 billion in 2024 and is projected to reach US$21.5 billion by 2030. Hormone receptor-positive/HER2-negative tumors constituted 57.25% of the HER2-negative breast cancer market size in 2025. Based on these figures, the global market for hormone receptor-positive/HER2-negative breast cancer was approximately USD 8.24 billion in 2025 (calculated as 57.25% of US$14.4 billion). OP-1250 specifically targets the recurrent, locally advanced, or metastatic forms within this broader ER+/HER2- breast cancer market. While a precise market size solely for this advanced stage sub-segment is not available, the figures for the overall ER+/HER2- breast cancer market indicate the significant scope of the disease area.

    AI Analysis | Feedback

    Olema Pharmaceuticals (OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, is poised for potential revenue growth over the next two to three years primarily through the successful advancement of its lead product candidates and strategic collaborations. While the company is currently pre-revenue from product sales, anticipated revenue drivers include:
    1. Successful Advancement and Potential Regulatory Milestones for Palazestrant (OP-1250): The most significant driver of future revenue growth for Olema Pharmaceuticals is the successful progression of its lead product candidate, palazestrant (OP-1250), through pivotal Phase 3 clinical trials and towards potential regulatory approval. Top-line data from the Phase 3 OPERA-01 monotherapy study is anticipated in the second half of 2026, which is a critical catalyst for validating the drug's potential. Additionally, the Phase 3 OPERA-02 trial, evaluating palazestrant in combination with ribociclib, is actively enrolling patients. Positive outcomes from these trials and the subsequent submission of a New Drug Application (NDA) to the FDA for potential approval, with preparations for a possible commercial launch set for late 2027, are crucial for future product-based revenue.
    2. Strategic Partnerships and Collaborations: Olema Pharmaceuticals has demonstrated a strategy of forging significant collaborations to advance its pipeline. The company has a collaboration with Novartis for the Phase 3 OPERA-02 trial. Such strategic partnerships can provide substantial upfront payments, research funding, and milestone payments upon the achievement of specific clinical, regulatory, or commercial goals. These payments are a key source of revenue for clinical-stage biopharmaceutical companies like Olema. There is also mention of a potential collaboration with Pfizer and an ongoing Phase 1b/2 study with atirmociclib.
    3. Progression of OP-3136 and Pipeline Expansion: Beyond palazestrant, the advancement of other pipeline candidates, such as OP-3136 (a potent lysine acetyltransferase 6 (KAT6) inhibitor), represents another potential driver of future revenue. Initial clinical results for OP-3136 are expected in the second quarter of 2026. Successful development of additional assets can broaden the company's therapeutic portfolio, enhance its attractiveness for new partnerships, and potentially lead to new revenue streams through licensing agreements or future product sales.

    AI Analysis | Feedback

    Share Repurchases

    No information available regarding share repurchases made or authorized by Olema Pharmaceuticals over the last 3-5 years.

    Share Issuance

    • In November 2025, Olema Pharmaceuticals closed a public offering of 11,500,000 shares of common stock, including the full exercise of the underwriters' option, resulting in gross proceeds of approximately $218.5 million.
    • Olema Pharmaceuticals completed an equity private placement in December 2024, raising approximately $250 million.
    • In January 2025, the company entered into agreements to exchange approximately 6,070,000 shares of its common stock for pre-funded warrants with Bain Capital, Paradigm BioCapital, and BVF Partners.

    Inbound Investments

    • Olema Pharmaceuticals secured a $250 million private placement in December 2024 with new and existing institutional and accredited investors, including Bain Capital Life Sciences and other firms, to fund its clinical endeavors.
    • The company forged a significant collaboration with Novartis in December 2024 to advance its pivotal Phase 3 OPERA-02 trial, combining palazestrant with ribociclib.
    • In November 2025, Olema Pharmaceuticals announced a new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib.

    Outbound Investments

    No information available regarding outbound investments made by Olema Pharmaceuticals over the last 3-5 years.

    Capital Expenditures

    • Olema Pharmaceuticals' net loss of $162.5 million in 2025 was primarily driven by $178.7 million in operating expenses, reflecting increased research and development (R&D) and clinical trial spending.
    • GAAP R&D expenses increased to $157.7 million for the full year 2025, up from $124.5 million in 2024 and $86.1 million in 2023, mainly due to increased spending on clinical operations and development activities for palazestrant and OP-3136.
    • In the second quarter of 2025, GAAP R&D expenses included a one-time milestone payment of $10 million made to Aurigene.

    Latest Trefis Analyses

    TitleDate
    0DASHBOARDS 
    1Olema Pharmaceuticals Earnings Notes12/27/2025
    Title
    0ARTICLES

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    UTZUtz Brands1.288.0%37.8%
    LCIDLucid2.458.4%-30.7%
    IOVAIovance Biotherapeutics2.339.4%100.7%
    AEHRAehr Test Systems3.037.4%389.9%
    XNCRXencor1.536.8%33.6%
    FEIMFrequency Electronics0.835.5%48.3%
    CDNACareDx2.033.2%104.6%
    MANManpowerGroup2.431.9%77.9%
    ELVAElectrovaya0.529.2%29.0%
    ATAIAtaiBeckley2.625.8%74.4%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    AIAIAIAI0.5-28.3%-55.1%
    PENGPenguin Solutions3.0-25.3%197.0%
    LINCLincoln Educational Services1.3-23.5%69.6%
    TENBTenable4.0-20.1%44.9%
    UTIUniversal Technical Institute2.1-20.0%42.8%
    SPIRSpire Global0.4-19.6%55.5%
    VICRVicor9.8-18.8%95.9%
    PNRPentair10.0-18.8%-40.6%
    ABSIAbsci1.3-18.7%138.4%
    BLZEBackblaze0.8-18.5%189.3%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    CRNXCrinetics Pharmaceuticals8.7133.9%80.2%
    TRAXFirst Tracks Biotherapeutics1.3114.5%100.9%
    UTZUtz Brands1.2101.2%37.8%
    DFTXDefinium Therapeutics, Inc.4.984.2%233.7%
    PBFPBF Energy7.777.1%147.1%
    ATAIAtaiBeckley2.675.7%74.4%
    MNPRMonopar Therapeutics1.068.3%73.9%
    ALITAlight9.965.0%-51.8%
    BLZEBackblaze0.864.6%189.3%
    ZBIOZenas BioPharma1.863.6%-10.9%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    FACFactorial Energy0.6-64.0%24.5%
    HTZHertz Global0.6-63.4%-64.0%
    AIAIAIAI0.5-59.2%-55.1%
    HYLNHyliion0.7-52.1%110.9%
    ALOYREalloys0.5-49.4%-4.7%
    ABTCAmerican Bitcoin6.6-49.3%-74.6%
    NVTSNavitas Semiconductor2.9-46.6%79.6%
    WOLFWolfspeed1.2-44.7%82.3%
    EOSEEos Energy Enterprises1.4-44.6%-63.0%
    YSSYork Space Systems2.2-41.6%-46.5%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    OLMAARVNVERUZYMEKPTICLDXMedian
    NameOlema Ph.Arvinas Veru ZymeworksKaryopha.Celldex . 
    Mkt Price11.598.262.3424.057.8735.669.93
    Mkt Cap1.20.50.11.80.22.40.9
    Rev LTM089081151141
    Op Inc LTM-202-254-28-114-84-309-158
    FCF LTM-149-257-26-78-59-226-113
    FCF 3Y Avg-120-289-32-78-100-174-110
    CFO LTM-149-254-26-75-59-222-112
    CFO 3Y Avg-120-286-32-75-100-171-110

    Growth & Margins

    OLMAARVNVERUZYMEKPTICLDXMedian
    NameOlema Ph.Arvinas Veru ZymeworksKaryopha.Celldex . 
    Rev Chg LTM--79.1%--13.0%6.3%-88.5%-46.0%
    Rev Chg 3Y Avg-123.9%--5.5%0.8%9.6%5.2%
    Rev Chg Q--91.7%--91.1%16.8%-97.8%-91.4%
    QoQ Delta Rev Chg LTM--66.0%--23.3%3.5%-44.0%-33.6%
    Op Inc Chg LTM-41.3%-165.4%30.1%-5.8%29.2%-42.3%-23.6%
    Op Inc Chg 3Y Avg-22.8%-41.6%35.7%-54.3%14.6%-38.9%-30.8%
    Op Mgn LTM--283.8%--140.2%-55.7%-35,688.5%-212.0%
    Op Mgn 3Y Avg--287.7%--183.4%-77.9%-13,678.4%-235.5%
    QoQ Delta Op Mgn LTM--238.7%--53.0%6.4%-17,100.7%-145.8%
    CFO/Rev LTM--284.2%--92.7%-39.1%-25,653.7%-188.5%
    CFO/Rev 3Y Avg--279.9%--106.0%-69.7%-9,962.8%-193.0%
    FCF/Rev LTM--287.4%--95.4%-39.1%-26,125.8%-191.4%
    FCF/Rev 3Y Avg--282.0%--110.8%-69.8%-10,136.9%-196.4%

    Valuation

    OLMAARVNVERUZYMEKPTICLDXMedian
    NameOlema Ph.Arvinas Veru ZymeworksKaryopha.Celldex . 
    Mkt Cap1.20.50.11.80.22.40.9
    P/S-5.9-22.11.12,741.014.0
    P/Op Inc-5.9-2.1-1.9-15.8-2.1-7.7-4.0
    P/EBIT-5.9-2.1-1.9-16.2-1.2-7.7-4.0
    P/E-6.4-2.4-3.9-17.5-0.9-8.4-5.2
    P/CFO-8.0-2.1-2.1-23.8-2.9-10.7-5.5
    Total Yield-15.5%-41.9%-25.9%-5.7%-112.5%-11.9%-20.7%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg-20.1%-38.1%-234.1%-8.1%-708.7%-9.2%-29.1%
    D/E0.00.00.10.01.30.00.0
    Net D/E-0.4-1.1-0.5-0.20.8-0.2-0.3

    Returns

    OLMAARVNVERUZYMEKPTICLDXMedian
    NameOlema Ph.Arvinas Veru ZymeworksKaryopha.Celldex . 
    1M Rtn21.9%7.7%-20.7%3.9%-12.8%10.0%5.8%
    3M Rtn-30.3%-22.2%-1.3%-14.9%-14.2%4.1%-14.6%
    6M Rtn-56.6%-31.3%-8.2%1.6%32.2%41.8%-3.3%
    12M Rtn152.5%9.8%-59.7%67.9%95.6%61.7%64.8%
    3Y Rtn25.3%-65.5%-81.9%205.6%-68.4%-2.1%-33.8%
    1M Excs Rtn21.8%7.6%-20.8%3.8%-12.9%9.8%5.7%
    3M Excs Rtn-35.7%-29.2%-9.3%-19.3%-17.7%-1.9%-18.5%
    6M Excs Rtn-65.5%-40.5%-21.2%-5.7%16.4%30.8%-13.5%
    12M Excs Rtn143.6%-6.9%-80.0%49.5%85.0%39.9%44.7%
    3Y Excs Rtn-25.2%-132.5%-147.5%137.8%-133.1%-71.0%-101.8%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q2
    Period End3/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/2023
    Filing Date5/12/20263/16/202611/10/20258/11/20255/13/20253/18/202511/12/20248/6/20245/8/20243/11/202411/7/20238/8/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-58-50-46-48-35-37-38-33-34-30-23-22
    Operating Income-58-50-46-48-35-37-38-34-34-30-23-22
    Net Income-53-46-42-44-30-34-35-30-31-27-22-20
    EPS-0.52-0.51-0.49-0.51-0.36-0.40-0.60-0.54-0.56-0.48-0.48-0.49
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-201-178-165-157-142-142-136-121-109-105-101-101
    Operating Income TTM-202-179-165-157-143-142-136-122-110-105-102-102
    Net Income TTM-185-162-150-142-129-129-123-110-99-97-96-97
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-66.5%-36.1%-22.1%-42.8%-1.4%-20.9%-61.4%-55.5%-16.1%-11.8%-0.5%35.3%
    Operating Income Growth-66.3%-36.2%-21.9%-42.7%-1.6%-20.9%-61.2%-55.2%-16.0%-11.7%-0.5%35.1%
    Net Income Growth-74.7%-37.2%-22.2%-44.1%1.9%-25.4%-60.7%-51.2%-9.5%-2.3%5.4%38.8%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash505505329362393434215239249262277167
    Total Debt444511222232
    Net Debt / (Cash)-501-501-324-357-392-433-213-237-247-259-274-165
    Cash Flows Quarterly            
    FCF from Operations-46-38-35-30-44-26-27-28-23-18-23-22
    Cash Flows TTM            
    FCF from Operations TTM-149-147-135-127-125-104-97-92-87-84-85-80
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-36.8%-34.8%-34.3%-38.5%-30.5%-35.7%-38.8%-37.6%-42.1%-40.5%-33.4%-34.1%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-32.0%-31.1%-30.9%-31.6%-31.2%-34.6%-35.1%-34.1%-33.6%-35.0%-36.4%-40.1%

    Segment Financials

    Assets by Segment
    $ Mil20252024202320222021
    Single segment533451277216296
    Total533451277216296


    Price Behavior

    Price Behavior
    Market Price$11.59 
    Market Cap ($ Bil)1.2 
    First Trading Date11/19/2020 
    Distance from 52W High-67.7% 
       50 Days200 Days
    DMA Price$11.75$17.39
    DMA Trendupdown
    Distance from DMA-1.3%-33.4%
     3M1YR
    Volatility61.7%160.3%
    Downside Capture185.84-73.03
    Upside Capture-20.8051.74
    Correlation (SPY)19.9%1.5%
    OLMA Betas & Captures as of 6/30/2026

     1M2M3M6M1Y3Y
    Beta0.820.981.631.320.180.81
    Up Beta4.043.613.172.832.701.08
    Down Beta2.790.65-0.020.58-0.610.09
    Up Capture-105%-21%65%4%49%125%
    Bmk +ve Days11244067140429
    Stock +ve Days12203256118369
    Down Capture-48%84%186%166%-132%105%
    Bmk -ve Days10172358112321
    Stock -ve Days9213169133373

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with OLMA
    OLMA163.8%160.0%1.11-
    Sector ETF (XLV)23.2%15.8%1.1313.2%
    Equity (SPY)20.3%12.6%1.191.3%
    Gold (GLD)21.6%28.1%0.695.8%
    Commodities (DBC)31.4%19.1%1.30-3.3%
    Real Estate (VNQ)15.0%14.0%0.768.7%
    Bitcoin (BTCUSD)-44.6%42.9%-1.258.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with OLMA
    OLMA-14.4%107.8%0.31-
    Sector ETF (XLV)6.1%15.0%0.2221.9%
    Equity (SPY)12.9%17.1%0.5819.5%
    Gold (GLD)17.3%18.4%0.766.2%
    Commodities (DBC)8.9%19.5%0.35-0.8%
    Real Estate (VNQ)2.9%18.9%0.0520.1%
    Bitcoin (BTCUSD)14.9%53.4%0.4613.5%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with OLMA
    OLMA-13.3%105.6%0.21-
    Sector ETF (XLV)9.9%16.6%0.4820.6%
    Equity (SPY)15.2%17.9%0.7218.9%
    Gold (GLD)11.2%16.1%0.576.8%
    Commodities (DBC)7.2%17.9%0.32-0.9%
    Real Estate (VNQ)5.1%20.7%0.2119.3%
    Bitcoin (BTCUSD)58.7%66.2%0.9912.3%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date6302026
    Short Interest: Shares Quantity14.0 Mil
    Short Interest: % Change Since 61520269.3%
    Average Daily Volume2.5 Mil
    Days-to-Cover Short Interest5.7 days
    Basic Shares Quantity102.8 Mil
    Short % of Basic Shares13.7%

    Earnings Returns History

    Updated 6/15/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    5/12/2026-6.0%-13.2%-33.9%
    3/16/202612.8%-4.3%10.8%
    1/12/2026-3.1%-7.2%-17.9%
    11/10/20254.2%0.6%267.4%
    8/11/202516.2%26.0%70.9%
    5/13/2025-3.8%8.5%-13.2%
    3/18/2025-0.7%1.2%2.9%
    11/12/2024-0.5%-24.4%-41.8%
    ...
    SUMMARY STATS   
    # Positive11109
    # Negative121314
    Median Positive6.8%5.5%21.1%
    Median Negative-6.3%-10.1%-19.3%
    Max Positive16.2%26.0%267.4%
    Max Negative-26.7%-36.7%-61.8%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    5/12/2026-6.0%-13.2%-33.9%
    3/16/202612.8%-4.3%10.8%
    1/12/2026-3.1%-7.2%-17.9%
    11/10/20254.2%0.6%267.4%
    8/11/202516.2%26.0%70.9%
    5/13/2025-3.8%8.5%-13.2%
    3/18/2025-0.7%1.2%2.9%
    11/12/2024-0.5%-24.4%-41.8%
    8/6/2024-9.9%-10.1%-15.1%
    5/8/2024-9.3%-9.2%21.0%
    3/11/2024-6.6%-14.8%-15.8%
    11/7/20233.1%-4.5%-29.8%
    8/8/202312.1%14.3%21.1%
    5/9/2023-8.7%-12.8%-9.9%
    3/9/20233.5%1.3%-12.8%
    11/8/2022-5.1%2.2%-20.8%
    8/9/2022-26.7%-23.9%-21.2%
    5/9/20226.8%6.8%94.2%
    2/28/202215.0%-6.4%-3.0%
    11/10/20211.2%-5.5%-61.8%
    8/10/20214.9%4.1%12.8%
    5/11/202113.0%13.0%37.1%
    3/17/2021-10.2%-36.7%-27.2%
    SUMMARY STATS   
    # Positive11109
    # Negative121314
    Median Positive6.8%5.5%21.1%
    Median Negative-6.3%-10.1%-19.3%
    Max Positive16.2%26.0%267.4%
    Max Negative-26.7%-36.7%-61.8%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    03/31/202605/12/202610-Q
    12/31/202503/16/202610-K
    09/30/202511/10/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/13/202510-Q
    12/31/202403/18/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/06/202410-Q
    03/31/202405/08/202410-Q
    12/31/202303/11/202410-K
    09/30/202311/07/202310-Q
    06/30/202308/08/202310-Q
    03/31/202305/09/202310-Q
    12/31/202203/09/202310-K
    09/30/202211/08/202210-Q
    06/30/202208/09/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    03/31/202605/12/202610-Q
    12/31/202503/16/202610-K
    09/30/202511/10/202510-Q
    06/30/202508/11/202510-Q
    03/31/202505/13/202510-Q
    12/31/202403/18/202510-K
    09/30/202411/12/202410-Q
    06/30/202408/06/202410-Q
    03/31/202405/08/202410-Q
    12/31/202303/11/202410-K
    09/30/202311/07/202310-Q
    06/30/202308/08/202310-Q
    03/31/202305/09/202310-Q
    12/31/202203/09/202310-K
    09/30/202211/08/202210-Q
    06/30/202208/09/202210-Q
    03/31/202205/09/202210-Q
    12/31/202102/28/202210-K
    09/30/202111/10/202110-Q
    06/30/202108/10/202110-Q
    03/31/202105/11/202110-Q
    12/31/202003/17/202110-K
    09/30/202011/19/2020424B4

    Insider Activity

    Updated 6/23/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202624.2524,767600,6005,650Form
    2Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202624.69233  Form
    3Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202623.0115,000  Form
    4Harmon, CyrusDirectSell121202626.8810,000268,80019,562,458Form
    5Harmon, CyrusDirectSell116202629.123,489101,60021,483,862Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202624.2524,767600,6005,650Form
    2Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202624.69233  Form
    3Mitchell, ShawnteCHIEF LEGAL OFFICERDirectSell305202623.0115,000  Form
    4Harmon, CyrusDirectSell121202626.8810,000268,80019,562,458Form
    5Harmon, CyrusDirectSell116202629.123,489101,60021,483,862Form
    6Kovacs, Shane William CharlesCH. OPERATING & FINANCIAL OFF.DirectSell115202628.73100,0002,873,0004,014,357Form
    7Kovacs, Shane William CharlesCH. OPERATING & FINANCIAL OFF.DirectSell115202628.013,822107,0546,714,753Form
    8Myles, David CCH. DISCOV. & NON-CLIN DEV OFFDirectSell114202628.8750,0001,443,65115,671,151Form
    9Myles, David CCH. DISCOV. & NON-CLIN DEV OFFDirectSell114202627.6050,0001,380,17814,982,136Form
    10Myles, David CCH. DISCOV. & NON-CLIN DEV OFFSee FootnoteSell114202628.3410,000283,4004,104,936Form
    11Harmon, CyrusDirectSell1229202528.532,88182,19521,148,119Form
    12Zojwalla, NaseemChief Medical OfficerDirectSell1223202527.6699,5092,752,419124,138Form
    13Zojwalla, NaseemChief Medical OfficerDirectSell1223202528.04100,0002,804,0001,514,076Form
    14Clark, Ian TDirectSell1223202529.73264,800  Form
    15Myles, David CCH. DISCOV. & NON-CLIN DEV OFFDirectSell1223202530.4651,0001,553,54416,811,199Form
    16Zojwalla, NaseemChief Medical OfficerDirectSell1223202528.2070,0001,973,7292,932,313Form
    17Harmon, CyrusDirectSell91820258.3310,00083,3006,198,686Form
    18Harmon, CyrusSee FootnoteSell91820258.323,08625,676973,673Form
    19Harmon, CyrusDirectSell91820258.0410,00080,4006,063,286Form
    20Harmon, CyrusSee FootnoteSell91820258.081,91415,465970,521Form

    Investor Activity (13F)

    Updated Jul 22, 2026
    13F holdings as of Mar 31, 2026 (Q1 2026)

    Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Defilade Capital Management, L.P.$22.4 Mil3.1%31ADD +21.9%13F
    Cormorant Asset Management, LP$58.1 Mil2.9%46ADD +41.8%13F
    BVF Inc/Il$79.0 Mil2.5%41Hold13F
    Paradigm Biocapital Advisors LP$119.6 Mil2.4%35ADD +6.3%13F
    Lightspeed Management Company, L.L.C.$20.2 Mil2.0%8TRIM -29.8%13F
    First Turn Management, LLC$11.5 Mil1.3%33ADD +24.4%13F
    Vivo Capital, LLC$10.0 Mil0.8%46Hold13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Cormorant Asset Management, LP$58.1 Mil2.9%46ADD +41.8%13F
    First Turn Management, LLC$11.5 Mil1.3%33ADD +24.4%13F
    Defilade Capital Management, L.P.$22.4 Mil3.1%31ADD +21.9%13F
    Paradigm Biocapital Advisors LP$119.6 Mil2.4%35ADD +6.3%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQAs OfFiling
    Catalio Capital Management, LP$6.7 Mil1.2%45ExitedDec 31, 202513F
    Lightspeed Management Company, L.L.C.$20.2 Mil2.0%8TRIM -29.8%Mar 31, 202613F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Paradigm Biocapital Advisors LP$119.6 Mil2.4%35ADD +6.3%13F
    BVF Inc/Il$79.0 Mil2.5%41Hold13F
    Cormorant Asset Management, LP$58.1 Mil2.9%46ADD +41.8%13F
    Defilade Capital Management, L.P.$22.4 Mil3.1%31ADD +21.9%13F
    Lightspeed Management Company, L.L.C.$20.2 Mil2.0%8TRIM -29.8%13F
    First Turn Management, LLC$11.5 Mil1.3%33ADD +24.4%13F
    Vivo Capital, LLC$10.0 Mil0.8%46Hold13F

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 7/21/2026